anastrozole / Generic mfg. - LARVOL DELTA

First-in-human evaluation of IL2RG blockade in patients with severe aplastic anemia that is refractory to or relapsed on immunosuppressive therapy (ASH 2025) - "Given that lymphocyte development, proliferation, and activity aremediated in large part by gamma chain (gc) cytokines (IL2, IL4, IL7, IL9, IL15, IL21), which share a commonreceptor subunit (interleukin 2 receptor subunit gamma; IL2RG), IL2RG blockade may provide an novelmeans to suppress pathogenic T cell responses in T cell-mediated diseases, like AA. Data from this first-in-human evaluation of REGN7257 in patients with IST-refractory or IST-relapsed SAA show that IL2RG blockade was generally well-tolerated with observed AEs being generallyconsistent with the underlying disease. Reductions in lymphocytes and changes in serum cytokines andinflammatory/effector molecules were consistent with drug activity. One patient achieved a partialhematologic response that waned as drug cleared, but returned with retreatment."

Clinical • First-in-human • P1 data • Anemia • Aplastic Anemia • Febrile Neutropenia • Immunology • Infectious Disease • Neutropenia • Thrombocytopenia • CD8 • IL15 • IL2 • IL21 • IL2RG • IL4 • IL7 • IL9

Occult Breast Cancer Diagnosed from a Solitary Scalp Metastasis without Axillary Lymph Node Involvement: A Case Report. (PubMed, Surg Case Rep) - "We report a rare case of OBC diagnosed based on a solitary scalp metastasis without ALNM. OBC without ALNM appears to favor luminal type and distinct metastatic sites, but further cases are needed to establish treatment strategies."

Journal • Breast Cancer • Gastric Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Drug utilisation evaluation of oral anticancer therapy in a south indian cancer centre (ESMO Asia 2025) - "Among targeted therapies, Gefitinib, Osimertinib, Crizotinib, Afatinib, Lorlatinib, and Nilotinib demonstrated consumption of 30 DDDs per patient over 30 days. Lower consumptions were observed with Lenvatinib and Cabozantinib with 13.3 DDDs and 11.25 DDDs per patient respectively. In the hormonal therapy group, Letrozole, Tamoxifen, Bicalutamide, Anastrozole, Enzalutamide, and Exemestane were all prescribed in line with WHO standards (30 DDDs per patient), whereas Abiraterone exhibited lower consumption of 15 DDDs per patient. Prescribing patterns and consumption metrics were largely consistent with WHO criteria, indicating rational oral anticancer drug use. Prescribing patterns and consumption metrics were largely consistent with WHO criteria, indicating rational oral anticancer drug use. Dose deviations occurred, though reasons were unclear and may relate to adverse effects, indication-specific or patient factors, or economic constraints. Further research is warranted..."

Oncology • Oral Cancer

Real-world outcomes of trastuzumab deruxtecan with or without endocrine therapy in her2-low, hormone receptor-positive metastatic breast cancer: a propensity-matched analysis (SABCS 2025) - P1 | "Real-World Outcomes of Trastuzumab Deruxtecan with or without Endocrine Therapy in HER2-Low, Hormone Receptor-Positive Metastatic Breast Cancer: A Propensity-Matched AnalysisAuthors (max 50): 21Michela Palleschia, Alberto Farolfia, Caterina Giannia, Giulia Miserocchia, Matilde Corianòb, Nicola Gentilic, Marita Mariottia, Giandomenico Di Mennaa, Olga Serraa, Chiara Casadeia, Francesca Rusconid, Alice Andalòc, Simone Sabbionia, Andrea Carlinia, Daniela Montanaria, Marianna Siricoa, Roberta Maltonia, Lorenzo Cecconettoa, Samanta Sartia, Filippo Merlonia , Antonino MusolinoaAffiliation:a Medical Oncology, Breast & GYN Unit IRCCS Istituto Romagnolo per lo Studio Dei Tumori (IRST) "Dino Amadori"b Medical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy.c Data Unit, IRCCS Istituto Romagnolo per lo studio dei Tumori (IRST) "Dino Amadori", Meldola, Italyd TriNetX, LLC, Cambridge, MA, USA Background:Combination therapy..."

Clinical • Metastases • Real-world • Real-world evidence • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Updated results and an exploratory analysis of ESR1m circulating tumor DNA (ctDNA) dynamics from SERENA-6, a phase 3 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1 mutations (ESR1m) during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2- advanced breast cancer (ABC) (SABCS 2025) - "Methods SERENA-6, a randomized, double-blind, phase 3 trial, enrolled pts with HR+/HER2- ABC who had received ≥6 months of 1L AI (anastrozole/letrozole) + CDK4/6i (palbociclib/ribociclib/abemaciclib). No new safety signals were observed. These results further support an early switch to CAMI + CDK4/6i during 1L therapy to delay disease progression."

Circulating tumor DNA • Clinical • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • CDK4 • ER • HER-2

Side effects of hormone therapy in patients with malignant breast neoplasm: a cross-sectional study. (PubMed, Rev Bras Enferm) - "all groups presented some side effects and there are some factors that can intensify these symptoms, therefore, health professionals should monitor these effects to intervene early."

Adverse events • Journal • Observational data • Breast Cancer • Fatigue • Musculoskeletal Diseases • Musculoskeletal Pain • Oncology • Pain • Solid Tumor

Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial (SABCS 2025) - P3 | "Giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), was shown to be more potent than other SERDs (Liang 2021; Bardia 2023) and demonstrated superior antiproliferative activity vs anastrozole in the neoadj coopERA BC trial (Hurvitz 2023)... Pts with Stage I-III ER+ HER2- eBC were randomized 1:1 to giredestrant 30 mg oral daily (with an LHRH agonist in pre- and peri-menopausal women, and men) or standard-of-care ET (tamoxifen or aromatase inhibitor) for 5 years (yr)... lidERA BC is the first Phase III trial to demonstrate benefit with an oral SERD in eBC. Giredestrant tx resulted in a statistically significant and clinically meaningful IDFS improvement vs standard-of-care ET in ER+, HER2- eBC. OS trended in favor of the giredestrant arm, and DRFI was improved vs standard-of-care ET."

Clinical • P3 data • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Lack of effects of S-equol-containing supplement on the pharmacokinetics of oral hormone therapy drugs for breast cancer. (PubMed, Cancer Chemother Pharmacol) - "S-equol-containing supplement has no clinically significant effects on the exposure of oral hormone therapy drugs for breast cancer. TRIAL REGISTRATION NUMBER AND DATE OF REGISTRATION: jRCTs031200084, August 13th, 2020."

Journal • PK/PD data • Breast Cancer • Musculoskeletal Diseases • Musculoskeletal Pain • Oncology • Pain • Solid Tumor

Aromatase inhibitors and medication-related osteonecrosis of the jaw: friends, foes, or bystanders? (PubMed, Crit Rev Oncol Hematol) - "Letrozole was the most frequently prescribed AI, followed by anastrozole and exemestane. MRONJ was reported in 43 studies, with 1,147 cases among 45,121 AI users (2.5% of AI users in the included samples), the majority of whom were concomitantly treated with zoledronic acid and/or denosumab...Data demonstrate the difficulty of disentangling the effects of AI from those of antiresorptive therapy in MRONJ pathogenesis. Future research should consider AI as potential confounders in analytical studies to clarify their independent contribution, if any, to observed MRONJ occurrences."

Journal • Review • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

ELEGANCE: Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia (clinicaltrials.gov) - P=N/A | N=2766 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Jul 2032 ➔ Dec 2032 | Initiation date: Jul 2025 ➔ Dec 2025 | Trial primary completion date: Jul 2032 ➔ Dec 2032

Trial completion date • Trial initiation date • Trial primary completion date • Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Dalpiciclib plus endocrine therapy as adjuvant treatment for HR+/HER2- early breast cancer: updated results from the phase 3, DAWNA-A trial (SABCS 2025) - P3 | "Methods Women aged 18-75 yrs, with HR+/HER2-, node-positive, stage II-III BC were randomized (1:1) to receive Dalp (125 mg QD, 3-wk on/1-wk off, for 2 yrs) or placebo, both with ET (letrozole 2.5 mg, anastrozole 1 mg, or toremifene 60 mg QD, or tamoxifen 10 mg BID, for ≥5 yrs). Conclusions Addition of Dalp to adjuvant ET contiuned to show clinically meaningful improvement in IDFS within and beyond the 2-yr treatment period, with a manageable safety profile. These findings support the adjuvant use of Dalp for HR+/HER2- EBC."

Clinical • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

A Phase II Adjuvant Trial Evaluating the Impact of Omitting Chemotherapy Based on Patient's Selection for Moderate to High-Anatomical Risk, Low-Genomic Risk, ER-positive, HER2-negative Breast Cancer with a Combination Regimen of Ribociclib and Optimized Endocrine Therapy - SELECT Trial (SABCS 2025) - P2 | "Optimized ET includes an oral aromatase inhibitor (letrozole or anastrozole) for all participants, with the addition of a GnRH agonist (goserelin) to achieve gonadal suppression in all men and premenopausal women. Recruitment is ongoing. Clinical trial information: NCT06953882."

Clinical • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

A Functional Reversal of Leptomeningeal Disease without CNS Directed Therapy (SABCS 2025) - "Additionally, zoledronic acid was initiated for her diffuse osseous disease. After 22 months, the patient remains on first-line therapy with anastrozole and palbociclib...In a prospective phase II trial, abemaciclib achieved CSF and brain metastasis concentrations well above the IC50 for CDK4/6 inhibition and was associated with clinical benefit in a subset of patients with brain and leptomeningeal metastases. Our patient's recovery challenges the conventional guidelines regarding recommendations of intrathecal and/or radiation therapy for LMD and supports further investigation into systemic CDK4/6 inhibition for select patients."

Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • HER-2

Carcinoma en Cuirasse (SABCS 2025) - "She was treated with adjuvant dose-dense doxorubicin and cyclophosphamide, followed by paclitaxel (ddAC-T). She then received adjuvant radiation therapy which was followed by anastrozole...She later switched from palbociclib to abemaciclib because of insurance issues, and continued exemestane and abemaciclib until progression of disease locally. Due to aversion to parenteral treatment, she was started on everolimus with exemestane instead. Unfortunately, she had further progression of disease locally at which time she agreed to treatment with fulvestrant and everolimus but had worsening of her carcinoma en cuirasse (Figure 1b). It is likely that she had poor disease control because of intermittent compliance with all of her treatment. She most recently received repeat palliative radiation followed by capecitabine with improvement of her skin lesions (Figure 1c)."

Breast Cancer • Oncology • HER-2

Cdk4/6 inhibitor in extensive cutaneous metastasis breast carcinoma: a case report (SABCS 2025) - "In April 2024, treatment was started with ribociclib 600 mg orally every 24 hours and letrozole 2.5 mg orally every 24 hours plus denosumab...The use of aromatase inhibitors (anastrozole and letrozole) in CMBC has been reported; however, treatment with modern CDK4/6 inhibitor-based therapy has not been reported, nor is there any experience with this presentation of the disease. Our case demonstrates that treatment with CDK4/6 inhibitor, achieving an adequate response in CMBC-HR-positive extensive disease and scalp."

Case report • Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR

Cdk4/6 inhibitor-induced interstitial lung disease: a rare but severe complication in breast cancer treatment (SABCS 2025) - "She received four cycles of neoadjuvant docetaxel/cyclophosphamide followed by bilateral mastectomy with reconstruction in October 2023.Pathology from the right total mastectomy revealed pT2N2a disease with 6/10 positive lymph nodes...The patient completed adjuvant radiation therapy in March 2024 and began aromatase inhibitor, anastrozole in November 2023, and CDK 4/6 inhibitor, abemaciclib in April 2024...The exact mechanisms underlying CDK4/6 inhibitor-induced pneumonitis and ILD remain unclear, and retrospective studies have found no significant correlation between ILD and risk factors such as smoking history, lung metastases, or prior thoracic radiotherapy. This emphasizes the need forearly recognition and multidisciplinary management involving medical oncology, pulmonology, and infectious disease teams."

Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR

Comparative Adherence to Adjuvant Hormonal Therapy and Associated Mortality in Male and Female Veterans with Breast Cancer: A Nationwide Cohort Analysis (SABCS 2025) - "Veterans diagnosed with breast cancer and prescribed adjuvant hormone therapy (tamoxifen,anastrozole, letrozole, or exemestane) between January 1, 2005, and December 31, 2019,were included. Adherence to hormone therapy significantly improves survival outcomes among veterans with breast cancer. While male veterans demonstrated higher adherence rates, gender was not independently associated with adherence after adjustment. Targeted interventions addressing adherence disparities—particularly among younger, Black, divorced/widowed individuals,and patients with uncertain staging—could improve outcomes and reduce health disparities."

Adherence • Clinical • Breast Cancer • Male Breast Cancer • Oncology • Solid Tumor

Retrospective study on breast cancer index testing in a community hospital and analyzing its impact on physician-decision making for extended endocrine therapy in early breast cancer (SABCS 2025) - "Endocrine therapy consisted of anastrozole (32%), letrozole (31%), tamoxifen (9%), and other agents. In this retrospective analysis, BCI testing significantly influenced physician decision-making, leading to changes in EET recommendations in 75% of cases. These findings support the clinical utility of BCI in guiding personalized treatment strategies and minimizing unnecessary therapy in early breast cancer management. It also highlights the importance of its standardization in a community hospital to prevent over-treatment as well as encourage long-term adherence in patients with EET recommendations."

Retrospective data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Feasibility of Telemonitoring of Personalized Circadian Rhythms in Patients with Early-Stage HR-Positive Breast Cancer Receiving Endocrine Therapy (SABCS 2025) - "All pts were on endocrine monotherapy: 5 anastrozole, 2 tamoxifen, 2 letrozole, and 2 exemestane. Telemonitoring of circadian rhythms using wearable sensors is feasible and well-tolerated in patients receiving ET for HR+ breast cancer. Preliminary data suggest excellent patient adherence and feasibility of such telemonitoring approach, as well as increased ET-related symptoms and sleepiness in the "late" as compared to "early" ET groups. Further analysis will explore circadian rhythm metrics and associations with ET-related symptom burden."

Clinical • Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Five-year analysis of distant disease-free survival (DDFS) across key subgroups from the phase 3 NATALEE trial of ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) in patients with HR+/HER2− early breast cancer (EBC) (SABCS 2025) - " In NATALEE, patients were randomized 1:1 to receive either RIB (400 mg/d, 3 wk on/1 wk off for 3 y) + NSAI (anastrozole 1 mg/d or letrozole 2.5 mg/d for ≥5 y) or NSAI alone; men and premenopausal women also received goserelin. In this prespecified 5-y analysis, with all patients off RIB treatment for a median of 2 y, the DDFS benefit with RIB + NSAI was sustained or improved compared with prior NATALEE analysis. This benefit was observed across all key subgroups, including N0 disease. These findings support the use of adjuvant RIB + NSAI to reduce distant recurrence risk in the NATALEE-eligible high-risk HR+/HER2− EBC population."

Clinical • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Survivor plots for quantitated adjunctive statistically standardized ER, PgR, and HER2 in adjuvant postmenopausal breast cancer: Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole (SABCS 2025) - P3 | "Survivor plots adjusted for baseline demographic and clinical characteristics provided similar indications of significance for standardized ER, PgR, and HER2 as those seen in multivariable models with both log-normal and Cox survival analyses. Higher PgR was associated with significantly better DDFS."

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR

An Exploratory Clinical Trial of CDK4/6 Inhibitor Dalpiciclib Combined with Aromatase Inhibitors as Neoadjuvant Therapy for Stage II-III HR-positive HER2-negative Breast Cancer (SABCS 2025) - "Participants receive dalpiciclib 150 mg/d (d1-21 every 28 days) + AIs (letrozole 2.5 mg/d, anastrozole 1 mg/d, or exemestane 25 mg/d); premenopausal women add ovarian suppression (goserelin/leuprolide). Conclusion Dalpiciclib combined with AIs demonstrates promising efficacy and manageable toxicity as neoadjuvant therapy for stage II-III HR+/HER2- breast cancer, offering a new chemotherapy-free option. Future research should focus on biomarker-guided patient selection, long-term outcomes assessment, and comparative trials with other neoadjuvant therapies, aiming to improve the treatment paradigm for HR+/HER2- breast cancer."

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Evaluating weight loss outcomes in patients with hormone receptor-positive breast cancer on endocrine therapy receiving concurrent weight loss medications (SABCS 2025) - "ET at weight loss medication initiation: anastrozole (n=17); exemestane (n=3), letrozole (n=2), fulvestrant (n=1); tamoxifen (n=1). The use of GLP-1 RAs or phentermine in this cohort of patients with HR+ BC on ET was associated with meaningful weight loss, most notably within the first nine months, with weight plateauing thereafter. The degree of weight loss observed was comparable to outcomes reported in the general population using these medications. Limitations include a small sample size and grouping of all weight loss agents together."

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Tolerance and clinical outcomes in elderly patients with hormone receptor positive breast cancer receiving CDK 4/6 inhibitors at a rural comprehensive cancer center (SABCS 2025) - "COX proportional hazard models did not show significant difference in survival outcomes in patients based on ADI (state ADI >5 or <5), age (less than 70 years vs. greater than 70 years), CDK 4/6i drug (abemaciclib vs. ribociclib vs. palbociclib), or endocrine therapy (anastrozole vs. fulvestrant vs. letrozole). This may be due, in part, to less fit patients and the presence of underlying comorbid conditions compared to more selective populations in pivotal trials. It is also possible that rurality itself may affect outcome measures in a distinct way that is not captured through ADI."

Clinical • Clinical data • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Impact of Glucagon-like peptide-1 receptor agonists Use on Survival and Metabolic Outcomes in Metastatic Estrogen Receptor Positive Breast Cancer: A Real-World Cohort Study (SABCS 2025) - "Two cohorts were defined: (1) ER+ MBC patients treated with GLP-1a (tirzepatide, dulaglutide, semaglutide, or liraglutide) and aromatase inhibitors (letrozole, anastrozole, or exemestane), excluding metformin users; and (2) ER+ MBC patients treated with aromatase inhibitors without GLP-1a or metformin. This large retrospective cohort analysis provides evidence suggesting that GLP-1a use in patients with ER+ metastatic breast cancer may offer survival benefits beyond their established metabolic indications. The association between GLP-1a use and improved two-year overall survival, as well as reduced hospitalizations and lower incidence of several treatment-related adverse events, is clinically significant and suggests a possible dual role for GLP-1a in addressing both metabolic and oncologic challenges in this population. Importantly, GLP-1a therapy was not associated with increased gastrointestinal or cardiac toxicity, reinforcing its safety profile when used alongside..."

Clinical • Metastases • Real-world • Real-world evidence • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER